CCCCC4 Therapeutics, Inc.
$2.85+26% 1Y
$2.85
$1.7152 weeks$4.67
The financials
C4 Therapeutics, Inc. by the numbers
C4 Therapeutics, Inc. (CCCC) reported revenue of $6.6M in Q2 2026 (quarter ended Jun 30, 2026), up 2.8% from the same quarter a year earlier. That came with net loss of $24M. For the full year FY2025, revenue was $36M (+1.0% year on year) and net income −$105M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $6.6M | $6.5M | +2.8% |
| Operating income | −$26M | −$29M | n/a |
| Net income | −$24M | −$26M | n/a |
| Diluted EPS | −$0.18 | −$0.37 | n/a |